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Abstract: The soluble urokinase plasminogen activator receptor (suPAR) has been detected in blood, plasma, serum, urine, ovarian 
cystic fluid, and cerebrospinal fluid. Elevated suPAR levels in plasma have been associated with negative outcomes in various diseases, 
such as bacteremia, sepsis, SIRS, cardiovascular disease, cancer, and tuberculosis. The primary aim of this study was to investigate 
whether suPAR can be detected in saliva from healthy individuals and thus, if saliva suPAR can be related to plasma suPAR, CRP, 
BMI, or gender. Blood and unstimulated whole saliva was collected from 20 healthy individuals (10 female and 10 male, median age 
of 28 years; range 21–41). CRP and suPAR were measured with ELISA in saliva and serum/plasma. suPAR was detected in all saliva 
samples in the 5.2–28.1 ng/mL range, with a median value of 17.1 ng/mL. Saliva suPAR was significantly higher (P , 0.001) but not 
correlated to plasma suPAR in healthy young adults with normal plasma suPAR levels. suPAR and CRP levels were correlated in blood 
but not in saliva. No correlation was found between BMI, age, or gender and suPAR in saliva.
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Introduction
The  urokinase-type  plasminogen  activator    receptor 
(uPAR) is present on various immunologically active 
cells  including  monocytes,  neutrophils,    activated 
T lymphocytes, and macrophages, and also on endothe-
lial  cells,  keratinocytes,  fibroblasts,  smooth  muscle 
cells, megakaryocytes, and certain tumor cells.1 uPAR 
consists of three homologous domains (DI, DII and DIII) 
and is linked to the cell surface by a glycosylphosphati-
dylinositol (GPI) anchor. Domain DI carries the main 
binding site for the urokinase-type plasminogen acti-
vator (uPA).2 The binding of uPA to its receptor uPAR 
mediates a variety of cellular activities like migration, 
adhesion, differentiation, and proliferation.1 A soluble 
bioactive form of uPAR (suPAR) is shredded or cleaved 
from the cell surface.1 Full-length suPAR (suPARI–III) 
consists of all three domains but lacks the GPI anchor 
and can be cleaved into two soluble forms, suPARII–III 
and suPARI.1 The soluble receptor has similar extra-
cellular functions as uPAR3 and has been detected in 
various body fluids, including blood, plasma, serum, 
urine, ovarian cystic fluid, and cerebrospinal fluid.1,4–6 
In healthy individuals, suPAR levels are quite stable in 
both blood and urine, however, suPAR levels increase 
with age and are slightly higher in plasma from females 
when  compared  to  males.7  Several  studies  indicate 
that an elevated suPAR level in plasma is associated 
with a negative outcome in various diseases, including 
Staphylococcus aureus bacteremia,8 systemic inflam-
matory response syndrome,9 cardiovascular disease,10 
cancer,11 and tuberculosis.12 Although suPAR is a sig-
nificant marker in plasma, there is at present no study 
on suPAR in saliva. There is a great interest in explor-
ing the utility of inflammatory biomarkers in saliva, 
since compared to blood drawing, saliva collection is 
simple and non-invasive and does not carry any of the 
inconveniences or risks of drawing blood. The primary 
aim of this study was to investigate whether suPAR 
can be detected in saliva from healthy individuals. Fur-
thermore, if that were the case, a possible correlation to 
plasma suPAR, saliva C-reactive protein (CRP), gen-
der, or BMI should be investigated.
Material and Methods
Sample collection
This study included a total of 20 healthy   volunteers 
(10  female  and  10  male)  with  a  median  age  of 
28 years; range 21–41 years. All participants gave 
  written    consent  and  the  study  was  conducted  in 
accordance with the sixth revision of the Declaration 
of Helsinki. Participants were students recruited at 
Malmö University; all were nonsmokers and asked to 
refrain from eating 12 h prior to the sample collection. 
Weight and height were measured. Saliva and blood 
samples were collected in the morning (8–10 a.m.). 
After centrifugation, serum and plasma aliquots were 
immediately frozen at −20 °C. Unstimulated whole 
saliva was collected from the individuals using an oral 
swab (5001.02, Salimetrics, PA, USA).   Participants 
rinsed their mouth with water and then the swab was 
placed under the tongue on the floor of the mouth for 
1–2 minutes. After collection, the swab was centri-
fuged at 1500× g for 15 minutes. Saliva aliquots were 
immediately frozen at −20 °C.
suPAr in plasma and saliva
Plasma  (EDTA)  and  saliva  suPAR  concentrations 
were  analyzed  using  a  commercially  available 
enzyme  immunoassay  (suPARnostic™,  Virogates, 
Copenhagen, Denmark) according to the manufactur-
er’s instructions. The assay is a double monoclonal 
antibody sandwich assay that measures all circulat-
ing suPAR, including intact and cleaved forms of the 
receptor. The suPARnostic™ ELISA is recommended 
for EDTA plasma samples and hence spike, recovery, 
and linearity of dilution experiments were performed 
with saliva samples to validate the assay. Briefly, six 
saliva samples (with low, medium and high suPAR 
levels) were diluted 1:2 and 1:4 with the manufac-
turer’s dilution buffer (PBS pH 7.4 with proprietary 
additives) and assayed after dilution. Linearity was 
defined relative to the calculated amount of suPAR 
based  on  the  standard  curve  and  was  assessed  by 
comparing  observed  vs.  expected  values  based  on 
undiluted  samples.  Spiked  samples  were  prepared 
by adding three different concentrations of a spike 
stock solution to six saliva samples. Recoveries for 
spiked  saliva  samples  were  calculated  by  compar-
ing observed vs. expected values based on the spiked 
controls. The diluent for the spike stock solution was 
the same as the standard diluent.
crP in serum and saliva
A  highly  sensitive  ELISA  for  determination  of 
the  CRP  concentration  in  human  serum  was  used 
(Oxis  International  Inc.,  CA,  USA)  according  to suPAr in saliva
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the   manufacturer’s instructions. CRP in saliva was 
  determined  with  a  sandwich  ELISA  designed  for 
measurement of saliva CRP (Salimetrics, PA, USA) 
according to the manufacturer’s instructions.
Statistical methods
All statistical analyses were performed with SPSS 
version 18. The linear association of variables was 
evaluated by using Pearson´s correlation coefficient 
(r). The significance was tested using the paired t-test; 
statistical significance was considered at P , 0.05.
Results
The results of CRP and suPAR measurements in blood 
and saliva are presented in Table 1.
suPAr in plasma
suPAR in plasma was in the 1.04–4.01 ng/mL range. 
As depicted in Figure 1 the results indicate signifi-
cantly different suPAR levels in plasma between male 
and female subjects, P = 0.03. However, no correla-
tion between BMI or age and suPAR in plasma was 
found.
suPAr in saliva
suPAR was detected in all saliva samples (Fig. 1) 
and  was  in  the  5.21–18.1  ng/mL  range;  median 
value = 17.1 ng/mL. Saliva suPAR was significantly 
higher  (P  ,  0.001)  but  not  correlated  to  plasma 
suPAR in this subject group (Fig. 2). No correlation 
was found between BMI, age, or gender and suPAR 
in saliva. One of the participants had a saliva suPAR 
level higher than 2 SD from the mean. Excluding 
this value affected the relationship between the gen-
ders, and then the saliva suPAR mean became higher 
in  female  (20.5  ng/mL)  than  male  (17.8  ng/mL) 
subjects.
Spike, recovery, and linearity of dilution   experiments 
were conducted with saliva samples in order to vali-
date and assess the accuracy of the suPARnostic™ 
ELISA. Values obtained for spiked samples are pre-
sented in Table 2; the recovery of added suPAR was 
in the 90%–93% range. Linearity of dilution experi-
ments resulted in 104% ± 6% recovery at 1:2 dilu-
tions and 102% ± 11% recovery at 1:4 dilutions. The 
results indicated that the suPARnostic™ ELISA accu-
rately measures suPAR in saliva. Additionally, suPAR 
in saliva collected with an oral swab was compared 
to saliva collected by passive drooling; both sampling 
methods yielded similar levels of suPAR.
suPAr and crP
Saliva  CRP  was  significantly  lower  (P  ,  0.001) 
than plasma CRP; saliva CRP was in the range 0.09–
90.9 µg/L, with a median value of 1.31 µg/L, while 
plasma CRP was in the range 0.03–3.71 mg/L, with a 
median value of 0.59 mg/L. No correlation between 
CRP in plasma and saliva was found. An interesting 
finding was that plasma CRP was strongly correlated 
to BMI; r = 0.70, P , 0.001 for the entire subject 
group and r = 0.95, P , 0.001 for the female group 
only.  A  moderate  positive  correlation  was  found 
between plasma suPAR and CRP (r = 0.67, P = 0.03) 
in the female group. suPAR and CRP in saliva were 
not correlated in these subjects.
Discussion
To our knowledge, this study is the first to show that 
suPAR can be detected in saliva. The results show that 
saliva suPAR levels are significantly higher but not 
correlated to plasma suPAR levels. This is surprising 
considering that the level of most biomarkers is often 
significantly  lower  in  saliva,  compared  to  plasma/
serum.  Although  some  molecules  diffuse  or  are 
Table 1. suPAr and crP in human saliva and blood.
Male (n = 10) Female (n = 10)
Range Median Mean (±sD) Range Median Mean (±sD)
Age (year) 27–41 35  34 ± 4.8 21–28 25    25 ± 2.8
BMI 25–31 27  28 ± 2.3 18–31 20    21 ± 3.8
Saliva-suPAr (ng/mL) 5.2–68 16  23 ± 19 8.2–43 17    20 ± 12
Plasma-suPAr (ng/mL) 1.0–2.0 1.6 1.6 ± 0.36 1.4–4.0 2.1   2.3 ± 0.81
Saliva-crP (µg/L) 0.05–61 2.6  10 ± 19 0.09–32 1.1   5.9 ± 10
Serum-crP (mg/L) 0.18–3.7 2.0 1.9 ± 1.2 0.04–2.6 0.12 0.46 ± 0.82gustafsson et al
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actively transported into saliva from blood,   others are 
synthesized by the salivary glands. The mode of entry 
of suPAR into saliva is not yet investigated, however, 
if saliva suPAR is locally synthesized, a correlation 
with plasma levels would not necessarily be expected. 
In the present study the participants had saliva suPAR 
concentrations that were about 12-fold higher than the 
corresponding plasma concentrations (Fig. 1). Such 
high concentrations of suPAR are not likely obtained 
without a high expression of uPAR in the oral   cavity. 
Information about uPAR expression in the gingival 
tissue  or  salivary  glands  is  limited,  but  its  ligand, 
uPA, is expressed in gingival tissues.13,14 Furthermore, 
  Virtanen el al15 showed that uPA is expressed in the 
secretory cells of the salivary glands and secreted at 
low levels in saliva. Considering the high levels of 
saliva suPAR found in the present study and the fact 
that full-length suPAR is able to bind uPA,16 an expla-
nation for the low saliva uPA levels might be that the 
suPAR-uPA complex cannot be detected by the assay 
used. The role of suPAR in saliva is still unknown and 
further investigations are needed to establish the rea-
sons for the high levels of saliva suPAR. It is worth 
stressing  that  an  elevated  suPAR  concentration  in 
saliva may be a consequence of periodontal inflam-
mation. Oral health status was not investigated in this 
study; it would be of substantial value to examine if 
periodontal conditions affect the saliva suPAR level.
Saliva  collection  is  non-invasive  and  easy  to 
perform  compared  to  blood  drawing,  but  little  is 
known  about  the  biomarker  expression  levels  in 
saliva. Saliva volume, viscosity, content of mucins, 
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Figure 2. correlation between saliva and plasma suPAr for female (A) 
and male (B).
Table 2. Spike and recovery results for saliva samples 
analysed  with  suPArnostic™  eLISA.  suPAr  levels  are 
presented as mean ± SD of six different saliva samples.
spike level  
ng/mL
expected  
ng/mL
Observed  
ng/mL
Mean  
recovery %
1.3 13.4 ± 5.9 12.5 ± 5.5 93
4.1 15.8 ± 5.6 14.1 ± 4.9 90
7.2 18.4 ± 5.7 16.9 ± 4.9 93
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Figure  1.  suPAr  levels  in  plasma  and  saliva  between  female  and 
male.  Solid  bars  indicate  mean  values.  suPAr  was  determined  by 
  suPArnostic™ eLISA.suPAr in saliva
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  abundance of particulate matter, and bacterial load 
vary considerably between individuals. These factors 
have  the  potential  to  influence  the  reliability  and 
validity of the measurements of saliva biomarkers. 
Saliva sample collection in this study was done with 
an oral swab; filtering saliva through an oral swab 
and centrifuging prior to the assay tend to minimize 
some of these sources of variation. Nevertheless, the 
swab collection yielded results similar to the ones 
from passive drooling collection (result not shown). 
Saliva suPAR was measured with the commercially 
available  suPARnostic™  ELISA,  developed  and 
recommended for EDTA-plasma. However, recovery 
studies show that saliva is a suitable medium for this 
assay. In addition, the same ELISA has been used 
to measure suPAR in urine4 and cerebrospinal fluid6 
with reproducible results.
According to Eugen-Olsen et al,7 a normal plasma 
suPAR range for healthy individuals 20–30 years of 
age, is 2.5–2.9 ng/mL for females and 1.5–2.5 ng/mL 
for males. Similar results have been found in this study 
with the exception of one female subject (age 24,   
BMI 31) who had a slightly high plasma suPAR value 
at 4.0 ng/mL, she also had a saliva suPAR level above 
mean (26 ng/mL). Likewise, the man (age 31, BMI 
28) with the highest plasma suPAR (2.0 ng/mL) also 
had the highest saliva suPAR among the male sub-
jects. Hence, it would be of considerable value to 
measure saliva suPAR in different populations, with 
expected high or low plasma suPAR.
CRP is an acute phase marker and currently the 
best quantitative measure of an ongoing inflamma-
tion and hence, associations between suPAR and CRP 
were investigated. CRP and suPAR levels were cor-
related in blood but not in saliva, among the females 
in this study. A number of studies focused on correla-
tions between CRP and suPAR in blood show con-
flicting results,11,17,18 for example, early studies done 
by Slot et al19 demonstrated that suPAR and CRP cor-
related in patients with rheumatoid arthritis but not in 
patients with reactive arthritis. A prospective cohort 
study by Eugen-Olsen et al7 including 2602 individu-
als (ages 41–71) established a moderate positive cor-
relation between CRP and suPAR in serum/plasma. 
Also, a lack of association between BMI and plasma 
suPAR but a correlation between BMI and CRP was 
demonstrated,  in  agreement  with  this  study.  Their 
theory was that CRP and suPAR may reflect different 
inflammatory aspects, and thus suPAR appears less 
related to dysmetabolic conditions.
In  the  present  study  there  was  no  saliva-serum 
CRP  correlation;  the  results  are  consistent  with  a 
previously  published  study20  which  also  measured 
saliva and plasma levels of CRP in a young healthy 
subject  group.  On  the  other  hand,  a  study  by 
Quellet-Morin et al21 observed a moderate to strong 
association  between  CPR  in  saliva  and  serum. 
A lower correlation was found at serum CRP levels 
below 2.0 mg/L in comparison to high CRP levels 
($2.0 mg/L), suggesting that the prediction of serum 
CRP levels from saliva CRP levels is more accurate at 
higher serum concentrations. In addition, Punyadeera 
et al22 demonstrated a correlation between saliva and 
serum CRP at serum concentrations above 5 mg/mL. 
In the present study none of the subjects had serum 
CRP  concentrations  higher  than  3.7  mg/L.  In 
healthy individuals, normal CRP levels are generally 
considered to be ,3 mg/L. Low-grade inflammation 
can produce minor elevations of CRP in the 3–10 mg/L 
range while CRP levels higher than about 10 mg/L 
are  typically  associated  with  infection.23  Salivary 
CRP  levels  in  the  present  study  are  in  agreement 
with previously published data by Dillon et al and 
Ouellet-Morin et al.20,21 Five of the participants had 
saliva CRP levels higher than 2 SD from the mean, 
ie, 6.2 µg/mL in healthy adults, according to the kit 
manufacturer.  Correspondingly  high  values  were 
not observed from serum CRP. The high CRP saliva 
samples  were  serially  diluted  and  re-analyzed;  the 
dilutions followed a linear scale. Nevertheless, there 
was  still  no  saliva-serum  CRP  correlation  when 
excluding those five extreme values from the analysis. 
Quellet-Morin et al21 also reported 10 (of totally 61 
participants) extreme saliva CRP values that could 
not be explained by biological or clinical variables 
(poor  precision  of  the  assay,  blood  contamination, 
saliva pH, or the participants health conditions).
In conclusion, our results indicate that suPAR lev-
els are higher in saliva than plasma but saliva and 
plasma  suPAR  are  not  correlated  in  healthy  young 
adults with normal plasma suPAR levels. It is obvi-
ous that correlations established in the present study 
are of limited value due to the small cohort. However, 
the results obtained point to some interesting issues 
to be explored in future studies. The mechanism by 
which suPAR is carried from blood to saliva needs to gustafsson et al
124  Biomarker Insights 2011:6
be further investigated, taking into consideration that 
elevated saliva suPAR levels may be a product of local 
synthesis in the gingival tissue or the saliva glands.
It has been suggested that plasma suPAR may be a 
general marker of low grade inflammatory processes 
and that elevated suPAR levels correlate with risks of 
developing cancer, diabetes, and cardiovascular dis-
ease in the general population.7,10,11 Hence, it would 
be of considerable value to explore if saliva suPAR 
also  could  be  a  marker  similar  to  plasma  suPAR; 
measuring saliva suPAR is straightforward and non-
invasive, facilitating screening in large populations.
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